Estrella Immunopharma, Inc.
NASDAQEstrella Immunopharma reports on May 22 after a brutal month for the stock — and the setup heading in is one of persistent price weakness against a borrow market that has quietly loosened. The price tells the clearest story. ESLA has fallen 35% over the past month to $1.11, with losses of nearly 12% in the past week alone and 8% in the final session before this preview. Peers have…
ESLA short interest
Full pulse commentary is for ORTEX subscribers. The live data picture for ESLA below stays open — short interest, options flow, signals, and historical context.
Sign up free to read pulse →Short interest % of float, cost to borrow, utilization, and put/call ratio for ESLA are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
Snapshot as of 20 May 2026
Estrella Immunopharma reports on May 22 after a brutal month for the stock — and the setup heading in is one of persistent price weakness against a borrow market that has quietly loosened. The price tells the clearest…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ESLA — free to start on ORTEX.
Sign up for free →Open ESLA on ORTEX